Contact Us

For further information about our company and NexoBrid™,
please contact us at:

Global Headquarters
MediWound Ltd.
42 Hayarkon Street,
Yavne, Israel 8122745
Tel: + +972 77 9714100
Fax: +972 77 9714111
e-mail: info@mediwound.com

European Headquarters
Tel:    +49 6142 176590
Email: infoeurope@mediwound.com

France
Tel:    +49 6142 176590
Email: infofrance@mediwound.com

Germany
Tel:    +49 1732983947
Email: infogermany@mediwound.com

Italy
Tel:    +39 3440608370
Email: infoitaly@mediwound.com

Spain
Tel:    +34 637784546
Email: infospain@mediwound.com

United Kingdom
Tel:    +44 7500875318
Email: infounitedkingdom@mediwound.com

NexoBridTM

MediWound’s innovative drug, NexoBrid™, was approved in December 2012 by EMA via a centralized procedure and was granted orphan indication for removal of eschar in adults with deep partial- and full-thickness thermal burns (also known as debridement)

Nexobrid

Read More…

Close Menu